Evidence map›Paper›PMID 32429359›Full record

ReviewCells2020

The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation.

Chiara Amoroso, Federica Perillo, Francesco Strati, Massimo C Fantini, Flavio Caprioli, Federica Facciotti

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 1 synthesis or guideline pooled it, 228 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Guardians within: Cross-talk between the gut microbiome and host immune system.World journal of gastrointestinal pathophysiology · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Review

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Chiara AmorosoDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
Federica PerilloDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
Francesco StratiDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.ORCID 0000-0001-7217-3355
Massimo C FantiniGastroenterology Unit, Duilio Casula Hospital, AOU Cagliari, 09042 Cagliari, Italy.
Flavio CaprioliDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, 20135 Milan, Italy.
Federica FacciottiDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.ORCID 0000-0002-2541-9428
European Institute of Oncology · ITUniversity of Cagliari · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations of the gut microbiota may cause dysregulated mucosal immune responses leading to the onset of inflammatory bowel diseases (IBD) in genetically susceptible hosts. Restoring immune homeostasis through the normalization of the gut microbiota is now considered a valuable therapeutic approach to treat IBD patients. The customization of microbe-targeted therapies, including antibiotics, prebiotics, live biotherapeutics and faecal microbiota transplantation, is therefore considered to support current therapies in IBD management. In this review, we will discuss recent advancements in the understanding of host-microbe interactions in IBD and the basis to promote homeostatic immune responses through microbe-targeted therapies. By considering gut microbiota dysbiosis as a key feature for the establishment of chronic inflammatory events, in the near future it will be suitable to design new cost-effective, physiologic, and patient-oriented therapeutic strategies for the treatment of IBD that can be applied in a personalized manner.

Indexed as

Gastrointestinal MicrobiomeImmunity, MucosalAnimalsDysbiosisHumansImmunologic FactorsInflammationIntestinesImmunologic FactorsFMTgut microbiomeinflammatory bowel diseaseslive biotherapeutic products

Identifiers

PMID32429359
PMCPMC7291275
OpenAlexW3025018074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.